*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
# 東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
**(Stock Code: 2348)**

**DATE OF BOARD MEETING**

The board of directors (the "**Board**") of Dawnrays Pharmaceutical (Holdings) Limited (the "**Company**") hereby announces that a meeting of the Board will be held on Friday, 27 March 2026, for the purpose of, among other matters, approving the announcement of the annual results of the Company and its subsidiaries for the year ended 31 December 2025 and considering the recommendation of payment of a final dividend, (if any).

By Order of the Board
**Dawnrays Pharmaceutical (Holdings) Limited**
**Pang Kit Ling**
*Company Secretary*

Hong Kong, 13 March 2026

*As at the date of this announcement, the Board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; two non-executive directors, namely Mr. Leung Hong Man and Mr. Hu Shuo; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.*

**for identification purpose only*